Featured in Life Sciences Review
Arctic Therapeutics (AT) is at the forefront of precision medicine, making significant strides in genomics and drug discovery. Recognized as one of the Top 10 Genomics Solutions Providers in Europe/UK for 2022, AT is transforming the treatment landscape for both common and rare diseases.
Innovative approaches and groundbreaking projects
Under the leadership of father-son team, Dr. Hakon Hakonarson and Ívar Hákonarson, AT has pioneered the development of AT-001, a promising treatment for hereditary cystatin C amyloid angiopathy (HCCAA) and other neurodegenerative disorders. This innovative approach leverages genetic data and advanced IT infrastructure to accelerate drug development, offering new hope for patients with historically incurable conditions.
AT’s mission revolves around three key pillars: genetically informed drug development, genealogy, and IT. By integrating high-quality genetic information, AT is able to develop, repurpose, and improve drugs with higher success rates and faster time to market. Their work has significant implications for treating a wide range of conditions, including dementia, autoimmune disorders, and acne.
Impactful achievements
The current AT pipeline includes five drugs targeting various conditions. Among these, AT-001 has shown promise in treating HCCAA and is moving towards addressing Alzheimer’s disease. AT-004, expected to be the first to market, targets acne vulgaris with impressive pre-clinical results showing no side effects. This drug also shows potential in treating other skin conditions like psoriasis and atopic dermatitis.
With a state-of-the-art ISO 15189:2012-certified medical laboratory in Iceland, AT ensures rigorous adherence to regulatory standards. This facility supports their extensive research and clinical trials, emphasizing ATI’s dedication to high standards and precision medicine.
AT’s strategic use of genealogy databases and IT infrastructure enhances their drug development processes, providing invaluable insights and increasing the likelihood of clinical success. Their innovative approach is paving the way for new treatments and improving patient outcomes globally.
Future prospects
AT’s forward-thinking strategies and robust pipeline demonstrate their potential to disrupt the medical landscape. The company’s emphasis on side-effect-free treatments and precision medicine sets them apart as leaders in the field. With upcoming clinical trials and ongoing research, AT is poised to bring transformative therapies to market, improving lives worldwide.
For more details, check out the full article in Life Sciences Review.
